Latest Breaking News On - Salim yazji - Page 1 : comparemela.com

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Salim-yazji
Safety-review-committee
Oncternal-therapeutics-inc
Nasdaq
Chief-medical-officer

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Carl-byrnes
Salim-yazji
Richard-vincent
Kemp-dolliver
Robert-burns
Jim-breitmeyer
James-breitmeyer
Hartaj-singh
Oncternal-therapeutics-inc
Nasdaq
Oppenheimer-company
International-students

Enrollment Continues in Study Evaluating ONCT-534 For Advanced Prostate Cancer

Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).

Salim-yazji
Ramesh-narayanan
Drug-administration
College-of-medicine
Oncternal-therapeutics-inc
University-of-tennessee-health-science-center
Cancer-research
Oncternal-therapeutics
Fast-track
Muirhead-endowed-professor
Tennessee-health-science-center
News

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Salim-yazji
Corey-davis
Richard-vincent
Exchange-commission
Oncternal-therapeutics-inc
Safety-review-committee
Nasdaq
Therapeutics-enrolls-patients
Third-dosing-cohort
Bayesian-optimal-interval
Chief-medical-officer

Oncternal Therapeutics reports patient death in CAR-T dose-escalation study

Oncternal Therapeutics reports patient death in CAR-T dose-escalation study
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Salim-yazji
Abbvie-imbruvica
Johnson
Md-anderson-cancer-center
Oncternal-therapeutics
Cancer-center